Efficacy and Safety Evaluation in Recurrent Wheezing Attacks

Phase 3

Completed

Conditions: Bronchospasm; Bronchiolitis
Bronchospasm; Bronchitis

Interventions: Biological: Biological vaccine

Registration Number: NCT01734811

Lead Sponsor: Inmunotek S.L.

Brief Summary: The study will be conducted in two hospitals of the same geographic area. It will be included children \<3-years-old with recurrent wheezing attacks, confirmed by the review of the medical records, in the previous 12 months or a shorter time for those younger than one year.

Detailed Description: This randomized, double-blind, placebo-controlled, parallel-group study will included 120 children \<3 years old with ≥3 episodes of wheezing during the previous year. They will receive active treatment or placebo for six months. The main outcome will be the number of wheezing attacks during one year. Other outcomes were duration and severity of wheezing attacks , symptom and medication scores, and use of health resources.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 120

Inclusion Criteria

Subjects whose parents /legal representative have given written informed consent.
Both gender
Subject up to 36 months of age.
Subjects with recurrent bronchospasms (wheezing attacks); 3 or more exacerbations in the last 12 months

Exclusion Criteria

Subjects whose parents/legal representative have not given written informed consent.
Subjects out of aged range
Subjects with malignancies or chemotherapy treatment
Subjects included in another clinical trial in the last 12 months.
Subject in immunosuppressive or immunostimulatory treatment
Subjects who have received iv gamma globulin in the past 12 months.
Subjects diagnosed with candidiasis or fungal recurrent infections.
Subjects diagnosed with malabsorption syndrome
Subjects with clinical allergy to common aeroallergens in the geographical area.
Subjects with hepatitis virus infections, HIV and tuberculosis

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Biological vaccine	Biological vaccine	The subjects will receive daily biological vaccines pray (2 puff of 100 µL) of for 6 months, followed by other 6 months of observation
Placebo	Biological vaccine	The subjects will receive daily placebo spray (2 puff of 100 µL) for 6 months, followed by other 6 months of observation

Primary Outcome Measures

Name	Time	Method
Number of Recurrent Bronchospasm (Wheezing Attacks)	12 months	Assessment of reduction of bronchospasm (wheezing attacks) episodes at 12 months. The number of bronchospasm (wheezing attacks) episodes, in active and placebo group will be compared

Secondary Outcome Measures

Name	Time	Method
Duration (Days) of Wheezing Attacks (WA)	12 months	Review of bronchospasm (wheezing attacks) duration per patient
Number of Days With Wheezing Attacks During the Study	12 months	Review of the number of days with wheezing attacks during the study
Symptom Score During Wheezing Attacks	12 months	Total of Symptom score during wheezing attacks. The patients were reviewed at our clinics every three months. These scores were recorded daily in a diary card by the parents, who were duly instructed. Scale use to evaluate symptom during wheezing attacks is called the Symptom scores (SS) scale. Minimum value is 0 (meant improvement) and maximum value (meant not improvement) is 3. The rating was: 0=absent (no sign/symptom evident); 1=mild (sign/symptom clearly present, but easily tolerated); 2=moderate (definite awareness of sign/symptom that is bothersome but tolerable) and 3=severe (sign/symptom that is hard to tolerate; causes interference with activities of daily life and/or sleeping). Fever was scored as number of days with temperature over 37ºC. The total symptom score was calculated as the sum of all individual scores during the wheezing attacks.
Time Until Appearance of First WA	12 months	time (days) until appearance of first wheezing attack (WA)
Number of Patients With Recurrent WA During the Study	12 months	Review of number of patients with recurrent WA during the whole study
Medication Score During WA	12 months	Review of medication consumption during wheezing attacks. The patients were reviewed at our clinics every three months. Medication scores were recorded daily in a diary card by the parents, who were duly instructed. Medication was rated from 0 (minimum value) and the maximum value correspond to the maximum medication consumed per 24h. Rating was according to Dreborg et al. with slight modifications: two points were given for one tablet of 4 mg of Montelukast, for one puff of 50 μg budesonide-equivalent or for one dose of oral prednisolone, and 3 for the inhalation of one puff of 200 μg budesonide-equivalent. In the case of antibiotics and antipyretic/-anti-inflammatory drugs, the number of daily doses of these drugs was recorded. The total symptom score was calculated as the sum of all individual scores during the wheezing attacks.
Overall Symptom Score	12 months	Review of symptoms during the whole study. The patients were reviewed at our clinics every three months. These scores were recorded daily in a diary card by the parents, who were duly instructed. Scale use to evaluate symptom during wheezing attacks is called the Symptom scores (SS) scale. Minimum value is 0 (meant improvement) and maximum value (meant not improvement) is 3. The rating was: 0=absent (no sign/symptom evident); 1=mild (sign/symptom clearly present, but easily tolerated); 2=moderate (definite awareness of sign/symptom that is bothersome but tolerable) and 3=severe (sign/symptom that is hard to tolerate; causes interference with activities of daily life and/or sleeping). Fever was scored as number of days with temperature over 37ºC. The total symptom score was calculated as the sum of all individual scores during the whole study
Overall Medication Score	12 months	Review of medication consumption during the whole study. The patients were reviewed at our clinics every three months. Medication scores were recorded daily in a diary card by the parents, who were duly instructed. Medication was rated from 0 (minimum value) and the maximum value correspond to the maximum medication consumed per 24h. Rating was according to Dreborg et al. with slight modifications: two points were given for one tablet of 4 mg of Montelukast, for one puff of 50 μg budesonide-equivalent or for one dose of oral prednisolone, and 3 for the inhalation of one puff of 200 μg budesonide-equivalent. In the case of antibiotics and antipyretic/-anti-inflammatory drugs, the number of daily doses of these drugs was recorded. The total symptom score was calculated as the sum of all individual scores during the whole study.